Immunic, INC 10-Q quarterly reports

Immunic, Inc. (IMUX) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development for its lead multiple sclerosis drug candidate, vidofludimus calcium, while reporting increased operating expenses and a net loss.

Immunic, Inc. details its Q1 2026 financial performance and ongoing clinical development of its novel oral therapies for neurologic and gastrointestinal diseases.

Immunic, Inc. reported increased net losses and a going concern warning, alongside a Nasdaq delisting notice, despite positive clinical trial updates for its lead drug candidates.

Immunic, Inc. reported increased losses and a going concern warning, despite positive clinical trial data and recent capital raises, while also receiving a Nasdaq minimum bid price non-compliance notice.

Immunic Inc. reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Immunic Inc. reports a net loss of $24.4 million for the third quarter of 2024, while highlighting progress in its clinical development programs.

Immunic Inc, a biotechnology firm specializing in oral immunology therapies, announced its second-quarter financial results and updates on its clinical development programs.

Immunic Inc. reported a net loss of $29.6 million for the first quarter of 2024, alongside updates on clinical programs and a significant private placement.